Novel combination of anticholineric and beta mimetics for the treatment of respiratory diseases
The present invention describes a combination of anticholinergic and β mimetics for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma. It further comprises the preparation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.
1 - 23 . (canceled)
24 . A combination of R,R-glycopyrrolate or a physiologically acceptable salt thereof and a long-acting β2-mimetic agent for the treatment of respiratory diseases, especially of inflammatory or obstructive diseases.
25 . The combination according to claim 24 wherein the β2-mimetic agent is selected from the group consisting of formoterol and salmeterol and their physiologically acceptable salts.
26 . The combination according to claim 25 wherein the β2-mimetic agent is formoterol or a physiologically acceptable salt thereof.
27 . The combination of claim 26 , wherein the daily dose of formoterol is from 1 to 72 μg.
28 . The combination according to claim 25 wherein the β2-mimetic agent is salmeterol or a physiologically acceptable salt thereof.
29 . The combination of claim 28 , wherein the daily dose of salmeterol is from 10 to 300 μg.
30 . The combination according to claim 24 , wherein the daily dose of R,R-glycopyrrolate is from 5 to 500 μg.
31 . The combination according to claim 24 , wherein the daily dose of R,R-glycopyrrolate is from 5 to 100 μg.
32 . A pharmaceutical for the treatment of allergies and respiratory diseases containing as active substances R,R-glycopyrrolate or a physiologically acceptable salt thereof and at least a long-acting β2 sympathomimetic.
33 . The pharmaceutical according to claim 32 that comprises R,R-glycopyrrolate and formoterol or their physiologically acceptable salts.
34 . The pharmaceutical according to claim 33 , wherein the active substances are available readily mixed in a fixed combination, if appropriate together with the usual excipients, adjuncts, and additives in a pharmaceutical form suitable for inhalative application.
35 . The pharmaceutical according to claim 33 , where the active substances are available in separate packaging units whereby both substances can be taken from the separate packaging units in such a way that they are available for simultaneous inhalative application.
36 . The pharmaceutical according to claim 35 , wherein the active substances can be administered independently from each other.
37 . The pharmaceutical according to claim 32 that is an inhalable aerosol with or without propellant.
38 . The pharmaceutical according to claim 32 that is an inhalable dry powder.
39 . The pharmaceutical according to claim 32 that is an inhalable suspension or solution.
40 . The pharmaceutical according to claim 32 presented in an inhaler.
41 . The pharmaceutical according to claim 40 comprising formoterol as β2 sympathomimetic.
42 . The pharmaceutical according to claim 40 comprising salmeterol as β2 sympathomimetic.
43 . The combination of claim 27 wherein the daily dose is from 3 to 50 μg.
44 . The combination of claim 43 wherein the daily dose is from 6 to 48 μg.
45 . The combination of claim 29 wherein the daily dose is from 25 to 200 μg.
46 . The combination of claim 45 wherein the daily dose is from 50 to 200 μg.
47 . The combination of claim 30 wherein the daily dose is from 15 to 300 μg.